The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index; 111 of the 122 sources its claims cite were checked for support.
Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span
Open accessAbstract
Senescence is the consequence of a signaling mechanism activated in stressed cells to prevent proliferation of cells with damage. Senescent cells (Sncs) often develop a senescence-associated secretory phenotype to prompt immune clearance, which drives chronic sterile inflammation and plays a causal role in aging and age-related diseases. Sncs accumulate with age and at anatomical sites of disease. Thus, they are regarded as a logical therapeutic target. Senotherapeutics are a new class of drugs that selectively kill Sncs (senolytics) or suppress their disease-causing phenotypes (senomorphics/senostatics). Since 2015, several senolytics went from identification to clinical trial. Preclinical data indicate that senolytics alleviate disease in numerous organs, improve physical function and resilience, and suppress all causes of mortality, even if administered to the aged. Here, we review the evidence that Sncs drive aging and disease, the approaches to identify and optimize senotherapeutics, and the current status of preclinical and clinical testing of senolytics.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review argues that senescent cells and their secretory phenotype causally contribute to aging and many age-related diseases, making them a therapeutic target. It surveys senolytic and senomorphic strategies, preclinical models, and early clinical trials, concluding that senolytics are promising but still need rigorous safety and efficacy testing.
Key findings
- Senescent cells accumulate with age and at disease sites; their senescence-associated secretory phenotype (SASP) drives chronic sterile inflammation, and transplanting as few as 1 million senescent cells into mice can induce frailty and age-related disease. Genetic clearance of p16-expressing cells extends health span and median life span in mice and improves metabolic, vascular, pulmonary, osteoarthritic, hepatic, and bone outcomes.
- Senolytics identified since 2015 include dasatinib plus quercetin (D+Q), fisetin, navitoclax and other BCL-2 family inhibitors, HSP90 inhibitors, and a p53–FOXO4 blocking peptide. A single D+Q administration after hind-limb irradiation in mice produced treadmill-performance benefit lasting over 1 year, consistent with a hit-and-run mechanism.
- Preclinical disease data include a 46% reduction in senescent osteocytes after genetic p16-cell clearance in old mice, with improved trabecular bone, cortical thickness, and bone strength. In an open-label diabetic kidney disease trial, adipose senescent-cell abundance and macrophage infiltration decreased 11 days after three daily D+Q doses; an idiopathic pulmonary fibrosis trial showed improved gait speed and chair-stand time.
- More than one dozen FDA-approved clinical trials have tested D+Q, fisetin, and UBX0101, but only three had reported results at the time of writing. UBX0101 results for osteoarthritis were disappointing; D+Q results were more promising; fisetin trials were under way for chronic kidney disease, skeletal health, frailty, osteoarthritis, and SARS-CoV-2 outcomes. One cited estimate is that a 2% delay in aging progression could yield 10 million more healthy elderly Americans and $7.1 trillion in savings over 40 years.
Methods
- This is a narrative review, not a primary experimental study; it synthesizes preclinical and clinical literature on cellular senescence and senotherapeutics.
- Evidence discussed includes transgenic mouse models (INK-ATTAC, p16-3MR, Ercc1−/Δ, BubR1H/H), rat models, human tissue explants, drug-library screens, and clinical trials.
- Senolytic discovery approaches described include bioinformatics-informed identification of senescent-cell antiapoptotic pathways, siRNA validation, screening with DNA-repair-deficient mouse embryonic fibroblasts and SA-βgal/C12FDG readouts, and optimization via medicinal chemistry, PROTACs, and prodrugs.
Limitations
- Stated in the paper: there is no single unambiguous senescence biomarker; accurate identification requires multiple markers, and most in vivo studies measure tissue homogenates rather than colocalizing markers in single cells. The authors call for cytometry by time of flight, single-cell omics, and other single-cell methods.
- Stated in the paper: clinical evidence is limited, with only three reported trials; UBX0101 was disappointing, D+Q findings are early, and more data are needed on safety, tolerability, side effects, and target engagement. The authors caution against self-medication or off-trial prescribing.
- Evident from the text: as a review, it does not use a systematic search or meta-analysis; many causal claims rest on animal models, and human data remain sparse. The paper also notes that senolytic activity varies by cell type and that some agents, such as navitoclax, can have off-target apoptotic effects on non-senescent cells.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
46 Partly supported · 37 Supported · 19 No basis given · 15 Own interpretation · 10 Not checked yet · 7 No full text of the sources · 4 Own result · 3 Not supported · 1 Couldn’t confirm · 1 Sources not found · 1 Own method · accuracy not yet measured
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Both of these prodrugs induced selective apoptosis of Sncs that was dependent on the presence of lysosomal β-galactosidase.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > APPROACHES TO IDENTIFY SENOLYTICS > Senolytic Optimization
What the sources say
- Disputedcites [77] sourceExperimental — accuracy not yet measured
In Results, “Senolytic properties of prodrug A depend on the lysosomal β-galactosidase” (page unavailable), GLB1 knockdown abolished prodrug A’s selective killing but did not affect the senolytic effect of ABT-263 (navitoclax). The paper treats ABT-263 as a comparator, not as a galactose-modified prodrug, so it contradicts the claim that both agents depended on lysosomal β-galactosidase. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Drugs with single or limited targets, such as Nutlin3a (an MDM2 inhibitor) or navitoclax (a BCL-2 inhibitor), can have off-target apoptotic effects on multiple non-Snc types, such as neutrophils and platelets in the case of navitoclax (75), making them panolytic.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > APPROACHES TO IDENTIFY SENOLYTICS > Further Development of Senolytics
What the sources say
- Disputedcites [75] sourceExperimental — accuracy not yet measured
The Discussion describes navitoclax’s effects on platelets as consistent with an on-target BCL-XL mechanism, not off-target apoptosis. It reports neutropenia but says only that it could result from BCL-2 inhibition; it does not establish apoptosis of neutrophils. The Research in Context interpretation likewise calls platelet and T-cell death targeted effects. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“One fundamental aging mechanism that underlies numerous age-related diseases is cellular senescence (5).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Cellular Senescence
What the sources say
- Partly supportedcites [5] sourceExperimental — accuracy not yet measured
The Cellular senescence section calls senescence a basic process that may contribute to age-related dysfunction and reports evidence that senescent cells drive multiple age-related pathologies. But it limits the clear experimental evidence to a progeroid mouse model and says it remains to be tested in chronologically aged models. The citing sentence states the broader role without those qualifications. (LLM, conf=0.85)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The recognition that old age is the greatest risk factor for most chronic diseases led to the geroscience hypothesis, which posits that therapeutically targeting fundamental aging mechanisms will successfully impact multiple chronic diseases because these diseases all share the same underlying mechanism (1).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Geroscience Hypothesis
What the sources say
- Supportedcites [1] source
The Introduction calls aging the predominant risk factor for most diseases that limit healthspan and describes geroscience as seeking multi-disease therapies. The Conclusions identify aging as a common cause and component of chronic diseases that interventions might target. This supports the claim as a statement of the geroscience hypothesis, not as proof that such therapies already work. (LLM, conf=0.90)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Sncs are often metabolically very active with a robust secretome [senescence-associated secretory phenotype (SASP)] (7).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Cellular Senescence
What the sources say
- Supportedcites [7] source
The section “The Secretory Phenotype of Senescent Cells” describes senescent cells as metabolically active and developing the SASP. “Specificity of the Senescence-Associated Secretory Phenotype” says a core of SASP factors is characteristic of senescent cells, while noting an exception for p16INK4a-induced senescence; this is consistent with “often.” Page numbers are not provided in our copy. (LLM, conf=0.94)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recent studies of animal models have established the veracity of the geroscience hypothesis (1).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Cellular Senescence
What the sources say
- Partly supportedcites [1] sourceExperimental — accuracy not yet measured
The Introduction reports that interventions extending lifespan in model organisms often delay or prevent chronic diseases, supporting the geroscience hypothesis. But the section on merging geroscience with human disease research cautions that mouse findings may not be validated in humans. Thus, the citing sentence’s claim that animal studies have “established the veracity” of the hypothesis is stronger than the source supports. (LLM, conf=0.84)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Persistent mitogenic signals, telomere shortening, DNA damage, high glucose, increased reactive oxygen species, or protein aggregation activates the p53/p21CIP1 and p16INK4a/Rb tumor suppressor pathways to initiate senescence (6)”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Cellular Senescence
What the sources say
- Partly supportedcites [6] sourceExperimental — accuracy not yet measured
The Discussion (pp. 4–6) links p53/p21 and p16/Rb to replicative senescence in cultured human fibroblasts. It does not establish that the listed stresses activate those pathways; it also reports that p16 rises after cells have exited the cell cycle, rather than showing that p16 initiates senescence. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“we and others demonstrated that inhibitors of BCL-2 family members, including navitoclax (ABT263), ABT737, A1331852, and A1155463, are senolytic in some but not all human cell types (27).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
What the sources say
- Partly supportedcites [27] sourceExperimental — accuracy not yet measured
The Introduction and Results report that navitoclax (ABT263) kills senescent HUVECs and IMR90 cells but not senescent human preadipocytes. Our copy does not establish senolytic activity in human cells for the other three named inhibitors, ABT737, A1331852, or A1155463. (LLM, conf=0.89)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“chronic clearance of p16-expressing cells in adult mice extends their median life span (9).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Cellular Senescence
What the sources say
- Supportedcites [9] source
The section “p16 Ink4a-positive cells shorten lifespan and healthspan” reports twice-weekly treatment from 12 months of age until death and median lifespan increases of 24% and 27% in the two mouse cohorts. The Discussion likewise reports median lifespan extensions after clearance of p16-positive cells. (LLM, conf=0.95)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Pharmacologic inhibitors of these proteins, similar to inhibition by small interfering RNA (siRNA), cause death of murine and human Sncs (19).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
What the sources say
- Supportedcites [19] source
The Results sections on candidate drugs in vitro and dasatinib and quercetin in vivo report selective killing of senescent human cells and reduced numbers of senescent mouse cells. The Abstract also states that drugs targeting the survival factors identified by siRNA killed senescent cells. Page numbers were not available in our copy. (LLM, conf=0.92)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Currently, the most widely used markers of cellular senescence include SA-βgal, which is measured at a higher pH than normal; the expression of cell cycle kinase inhibitors p16INK4a and p21CIP1; the absence of proliferation markers such as Ki67, markers of DNA damage such as p53, p-p53, γH2AX foci, TAFs, and SAHFs; the nuclear exclusion of HMGB1; the loss of Lamin B1 expression; the presence of”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > MEASURING SENESCENCE > Multiple Markers of Senescence
What the sources say
- Partly supportedcites [30] sourceExperimental — accuracy not yet measured
The sections ‘Challenges to Detect Senescent Cells in Humans’ and ‘Conclusions, Open Questions, and Perspectives’ recommend SA-β-gal, p16, p21, Ki67, lamin B1 and SASP markers; ‘Macromolecular Damage’ and ‘Chromatin Landscape’ discuss DNA-damage foci and SADS. Our copy does not substantiate HMGB1 nuclear exclusion or establish that every listed feature is among the most widely used markers. It also cautions that no single marker is completely specific for senescence. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Conversely, transplantation of as few as 1 million Sncs into a mouse is sufficient to drive frailty and age-related disease (17).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Cellular Senescence
What the sources say
- Partly supportedcites [17] sourceExperimental — accuracy not yet measured
The Results report that transplanting 1 million senescent cells into young mice reduced walking speed, hanging endurance, and grip strength, supporting the frailty-related part of the claim. But the Results section on older mice says disease burden at death was not significantly altered by transplantation, so the claim that it caused age-related disease is not supported. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Clearing Sncs from aged INK-ATTAC mice improves age-related changes in metabolic function (11)”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Cellular Senescence
What the sources say
- Supportedcites [11] source
The Results section (page not supplied) reports that clearing senescent cells in 18-month-old INK-ATTAC mice blunted fat loss, reduced circulating activin A, and increased adipogenic markers. These findings support the cited statement about improved age-related metabolic changes, particularly in adipose tissue. (LLM, conf=0.91)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Obviously, none of these markers are unique to Sncs.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > MEASURING SENESCENCE > Multiple Markers of Senescence
What the sources say
- Partly supportedcites [33] sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) shows that macrophages can display p16(Ink4a) and β-galactosidase, so those commonly used markers are not unique to senescent cells. The Introduction lists other markers but says only that none is a universal hallmark of senescent cells; that does not establish that every listed marker also occurs in non-senescent cells. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Screening a small library of autophagy regulators revealed HSP90 (heat shock protein 90) inhibitors as potent senolytics (20).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
What the sources say
- Supportedcites [20] sourceExperimental — accuracy not yet measured
The Results describe screening a 97-compound library of autophagy regulators and identifying HSP90 inhibitors that selectively reduced senescent-cell viability. The Discussion reports dose-dependent senolytic effects at nanomolar concentrations, supporting the description of them as potent senolytics. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“IKK/NF-κB and JAK inhibitors also suppress the SASP (11).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
What the sources say
- Partly supportedcites [11] sourceExperimental — accuracy not yet measured
The Results section says JAK inhibition suppresses SASP factors, including IL-6 and TNFα, in senescent fat progenitors; the Discussion also says JAK inhibitors blunt the SASP. The passages do not address IKK/NF-κB inhibitors, so that part of the cited claim is unsupported by this paper. (LLM, conf=0.87)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The HSP90 inhibitor 17-DMAG extends the health span of progeroid mice (20).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
What the sources say
- Supportedcites [20] source
The Results section (‘HSP90 inhibitor delays the onset of several age-related symptoms in Ercc1−/Δ mice’) reports that 17-DMAG significantly reduced a composite score of age-related symptoms in a progeroid mouse model and describes this as a healthspan improvement. The Discussion likewise states that intermittent 17-DMAG treatment improved healthspan in progeroid mice. (LLM, conf=0.95)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This approach revealed that Sncs express prosurvival proteins that block apoptosis of Sncs.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
What the sources say
- Supportedcites [19] source
The Results section (‘The senescent transcriptome and anti-apoptotic pathways’; page not provided) reports increased expression of anti-apoptotic genes in senescent cells. The Discussion (page not provided) reports that targeting pro-survival mechanisms selectively clears these cells and identifies p21, PAI-2, and BCL-xL proteins, supporting the paraphrase. (LLM, conf=0.91)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Fisetin, a quercetin-related natural flavonoid, has both senolytic and senomorphic activity depending on the cell type (21, 22).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
What the sources say
- Could not verifycites [21] sourceExperimental — accuracy not yet measured
The Abstract and Results describe piperlongumine’s senolytic effects in WI-38 fibroblasts, not fisetin’s effects. Searches of our full-text copy for “fisetin” and for its proposed senolytic and senomorphic activity found no passage addressing the claim. (LLM, conf=0.76)
- Partly supportedcites [22] sourceExperimental — accuracy not yet measured
The Results report that fisetin selectively reduced the viability of senescent HUVECs, but not senescent IMR90 cells or primary human preadipocytes; the Discussion describes this as cell-type-specific senolytic activity. The paper does not establish that fisetin has senomorphic activity in the other cell types, so it supports only the senolytic part of the claim. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“Drugs that target these pathways also have senolytic activity in vivo.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
What the sources say
- Supportedcites [19] source
The Results section, “Dasatinib and quercetin reduce senescent cells in vivo” (page unavailable), reports that the drug combination reduced senescent-cell markers in old mice. The Abstract also states that the combination reduced senescent-cell burden in aged, radiation-exposed, and progeroid mice. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Cellular senescence is implicated in the progression of liver disease.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Liver
What the sources say
- Could not verifycites [63] Rudolph D, 2000, Genes Dev sourceExperimental — accuracy not yet measured
The “Liver degeneration in NEMO/IKKγ-deficient embryos” section attributes liver damage in mutant embryos to apoptosis, but does not address cellular senescence or the progression of liver disease. Searches for “cellular senescence liver disease progression” and “senescence senescent cells” found no passage addressing that link. (LLM, conf=0.76)
- Partly supportedcites [64] sourceExperimental — accuracy not yet measured
The Results (no page supplied) show increased hepatocyte senescence in chronically inflamed mouse livers and impaired liver regeneration. The Discussion mentions liver disease as a condition possibly associated with senescence, but the paper does not examine whether senescence contributes to the progression of liver disease. (LLM, conf=0.82)
- Supportedcites [65] source
The Discussion links ageing with chronic liver disease and HCC, and reports increased cellular senescence in the livers of nfkb1-deficient mice that develop age-dependent liver lesions. This supports the broad, hedged statement that senescence is implicated in liver-disease progression; it does not establish senescence as a cause. (LLM, conf=0.85)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Chronic, intermittent D+Q treatment alleviates metabolic dysfunction in genetically or diet-induced obese mice or mice transplanted with Snc preadipocytes (17, 42).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Adipose Tissue
What the sources say
- Partly supportedcites [17] sourceExperimental — accuracy not yet measured
The Results section on senescent-cell transplantation reports that D+Q improved physical function in transplanted mice, but describes a single short course, not chronic intermittent treatment or an improvement in metabolic dysfunction. The Results section on aged mice reports intermittent D+Q treatment for four months in non-transplanted wild-type mice. Our copy does not report the claimed metabolic benefit in genetically or diet-induced obese mice. (LLM, conf=0.88)
- Partly supportedcites [42] sourceExperimental — accuracy not yet measured
The Results section, “Senescent cell clearance improves glucose homeostasis and insulin sensitivity” (page unavailable), reports improved glucose tolerance and insulin sensitivity in diet-induced obese mice treated with D+Q; the Discussion says D+Q was given intermittently. The cited copy does not establish the claimed D+Q benefit in genetically obese mice or mice transplanted with senescent preadipocytes. Its Figure 5 instead identifies ganciclovir as the treatment used in the genetically obese db/db mice shown there. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Transplanting senescent adipocyte precursors into young animals induces an aging-like phenotype with accelerated onset of multiple age-related diseases and premature death (17).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Adipose Tissue
What the sources say
- Partly supportedcites [17] sourceExperimental — accuracy not yet measured
The Results section reports that transplanting senescent preadipocytes into young mice caused lasting physical dysfunction. It reports increased mortality in 17-month-old recipients, not young ones, and says disease burden and causes of death were not significantly altered. The claimed earlier onset of multiple age-related diseases is therefore unsupported. (LLM, conf=0.91)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Importantly, clearance of Sncs either genetically or pharmacologically in mice leads to functional improvements in models of neurodegenerative diseases such as PD and AD (57–59).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Brain
What the sources say
- Partly supportedcites [57] sourceExperimental — accuracy not yet measured
The Introduction and Results report that pharmacological senolytic treatment in a mouse model of tau-associated neurodegeneration reduced neurofibrillary tangles, brain atrophy, and neuron loss. The paper does not report Parkinson’s disease models, genetic clearance of senescent cells in a neurodegeneration model, or measured improvements in mouse function; its genetic intervention reduced NFTs rather than directly clearing senescent cells. (LLM, conf=0.86)
- Partly supportedcites [58] sourceExperimental — accuracy not yet measured
In the main text (page unavailable), genetic clearance of senescent cells in PS19 tauopathy mice mitigated short-term memory loss. The ABT263 experiment in the same model reduced tau phosphorylation, but the paper does not report a functional improvement from pharmacological clearance. It does not test clearance in a Parkinson’s disease model or identify PS19 as a separate Alzheimer’s disease model. (LLM, conf=0.88)
- Partly supportedcites [59] sourceExperimental — accuracy not yet measured
The Results and Discussion (page not available in our copy) report that pharmacological senolytic treatment removed senescent cells and improved learning and memory in APP/PS1 Alzheimer’s-model mice. The Discussion also describes genetic clearance in other AD studies, but this paper does not report functional improvement after senescent-cell clearance in a Parkinson’s model, so it supports only part of the sentence attributed to the citation group. (LLM, conf=0.86)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Obesity accelerates the accumulation of Sncs in multiple tissues (15), including the brain.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Brain
What the sources say
- Partly supportedcites [15] sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports senescent cells in the livers of high-fat-fed mice, supporting an obesity-related link to senescence in the liver. It does not establish that obesity accelerates senescent-cell accumulation across multiple tissues or in the brain; its mention of clearance in multiple tissues concerns a different intervention. (LLM, conf=0.79)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“p21Cip1 is significantly increased predominantly in osteocytes (45).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Bone
What the sources say
- Supportedcites [45] source
The Results report that p21 expression was significantly higher in osteocytes from old versus young male mice. Among the isolated cell populations compared, osteocytes are the population identified as having a significant p21 increase. (LLM, conf=0.91)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Increased hepatocyte Snc burden is observed during aging and obesity in mice (15) and in chronic parenchymal liver disorders in humans such as chronic viral hepatitis (66), alcohol-related liver disease (65), NAFLD (15, 67), and genetic hemochromatosis (68).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Liver
What the sources say
- Supportedcites [15] source
The Results section reports that a high-fat diet increased multiple hepatocyte senescence markers in mice, while the Discussion describes hepatocyte senescence during mouse aging. The Results also report increased senescence markers in hepatocytes from patients with more severe NAFLD. The citing sentence assigns the other human liver disorders to different references, not this paper. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [66] source
- Partly supportedcites [65] sourceExperimental — accuracy not yet measured
Citation (65) is attached to the alcohol-related liver disease example, not the other conditions in the sentence. The Results section, “Neutrophils promote hepatocellular telomere damage” (page not provided), reports clusters of hepatocytes with telomere-associated DNA damage in human alcoholic liver disease, compared with negligible TAF-positive hepatocytes in normal liver. It does not establish that those hepatocytes were senescent, so the claim of increased senescent-cell burden is not fully supported. (LLM, conf=0.84)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Transplantation of senescent syngeneic preadipocytes or autologous ear fibroblasts into young adult mice impairs grip strength and measures of physical function, including walking speed and hanging endurance (17).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Skeletal Muscle
What the sources say
- Partly supportedcites [17] sourceExperimental — accuracy not yet measured
The Results sections report that senescent preadipocytes reduced walking speed, hanging endurance, and grip strength in young adult mice. They also report those impairments after transplantation of autologous senescent ear fibroblasts, but those recipients were placed on a high-fat diet; the citing sentence omits that condition for the fibroblast finding. No page numbers are available in our copy. (LLM, conf=0.84)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“p16Ink4a is significantly increased in osteoprogenitors, osteoblasts, and osteocytes from old mice compared with those from young mice (45).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Bone
What the sources say
- Supportedcites [45] source
The Results report significantly higher p16Ink4a expression in osteoblast progenitors, osteoblasts, and osteocytes from old (24-month) versus young (6-month) male mice, with similar findings in females. This directly supports the cited comparison. (LLM, conf=0.95)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Neurons microdissected from postmortem human brain with AD exhibit increased expression of senescence markers (57).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Brain
What the sources say
- Partly supportedcites [57] sourceExperimental — accuracy not yet measured
The Results section reports that microdissected, NFT-containing neurons from postmortem AD brains had upregulated genes in pathways resembling cellular senescence, compared with adjacent neurons without tangles (page unavailable). The claim omits that restriction and describes the result as increased expression of senescence markers, whereas this analysis reports a senescence-like gene-expression profile. (LLM, conf=0.82)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The same SASP factors are upregulated in bone marrow–derived myeloid cells but not in lymphocytes from old mice relative to those from young mice (45).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Bone
What the sources say
- Supportedcites [45] source
The Results report that several SASP factors elevated in old osteocytes were also significantly upregulated in old versus young myeloid cells. The same section reports relatively few significant age-related changes in B or T cells, supporting the contrast with lymphocytes. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Adipose tissue from mice treated with D+Q have significantly decreased p16Ink4a-, centromere binding protein (Cenbp)-, and p21Cip1-expressing Sncs (42).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Adipose Tissue
What the sources say
- Supportedcites [42] source
The Results section (‘Senescent cell clearance improves glucose homeostasis and insulin sensitivity’) reports that, after a single course of D+Q, adipose-tissue senescent cells highly expressing p16Ink4a-promoter-driven FLAG, CENP-B, or p21Cip1 decreased significantly. The p16 measure was promoter-driven FLAG rather than a direct measurement of p16Ink4a expression. (LLM, conf=0.91)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“There is also a causal link between senescence and neuropsychiatric disorders, such as anxiety, in the context of obesity (34).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Brain
What the sources say
- Supportedcites [34] source
The Abstract reports that clearing senescent cells in obese mice alleviated anxiety-related behavior and calls senescent cells major contributors to obesity-induced anxiety. The Results section on behavioral changes likewise reports reduced anxiety-like behavior after senescent-cell clearance, supporting the claimed causal link in the context of obesity. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Senescence of preadipocytes is a major negative regulator of adipogenesis through both cellautonomous and paracrine mechanisms, as demonstrated in coculture experiments (11).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Adipose Tissue
What the sources say
- Supportedcites [11] source
In Results, “Senescent fat cell progenitors impede adipogenesis” (page not provided), senescent source cells differentiated less than non-senescent controls, supporting the cell-autonomous part. In the same co-culture experiments, only 20% of nearby target progenitors accumulated lipid with senescent cells, versus more than 50% with non-senescent cells, supporting the paracrine part. (LLM, conf=0.91)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescence has been observed in neurons, astrocytes, microglia, oligodendrocytes, and oligodendrocyte progenitor cells (57–59).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Brain
What the sources say
- Partly supportedcites [57] sourceExperimental — accuracy not yet measured
The Results section reports a senescence-like transcriptomic profile in NFT-bearing neurons from Alzheimer’s disease brains. The paper mentions astrocytes and microglia in relation to inflammation, but does not report senescence in them, oligodendrocytes, or oligodendrocyte progenitor cells (no page numbers available in our copy). (LLM, conf=0.87)
- Partly supportedcites [58] sourceExperimental — accuracy not yet measured
The main text reports senescence-associated findings in astrocytes and microglia of PS19 mice. It reports no comparable induction in oligodendrocytes or neuron-enriched cells, and does not report senescence in oligodendrocyte progenitor cells. Thus this source supports two of the five cell types listed, not the full sentence. (LLM, conf=0.90)
- Partly supportedcites [59] sourceExperimental — accuracy not yet measured
The Results (page unavailable) document senescent oligodendrocyte progenitor cells, and the Discussion (page unavailable) reports evidence of astrocyte and microglial senescence in other studies of tau-mutant mice. The paper does not establish senescence in mature oligodendrocytes or neurons; it cautions that neuronal SA-βGal staining can occur without other senescence phenotypes. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Satellite cells derived from geriatric mice (28–32 months of age) exhibit elevated expression of p16Ink4a (53).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Skeletal Muscle
What the sources say
- Partly supportedcites [53] sourceExperimental — accuracy not yet measured
The opening passage and “Satellite Cell Geroconversion” report elevated p16Ink4a in satellite cells from geriatric mice, including high expression under proliferative pressure. Our copy does not specify that those mice were 28–32 months old, so the age range in the citing sentence is not verified. (LLM, conf=0.84)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Sncs can directly cause insulin resistance through release of SASP factors such as IL-6 and TNF-α (39, 40).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Adipose Tissue
What the sources say
- Partly supportedcites [39] sourceExperimental — accuracy not yet measured
The “Senescent Preadipocytes Develop a SASP” section reports increased secretion of IL-6 and increased TNF-α mRNA in senescent preadipocytes. The “Senescent Preadipocytes Induce Inflammation in Adjacent Cells” section shows that their conditioned medium induces inflammation, but the paper does not establish that these factors directly cause insulin resistance or demonstrate TNF-α secretion. (LLM, conf=0.88)
- Could not verifycites [40] sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) concerns macrophage-secreted factors, activin A, and adipose-progenitor differentiation; it mentions TNF-α as a possible stimulus for activin A expression. Searches for senescent cells, SASP, IL-6, and insulin resistance found no passage linking senescent-cell secretions to insulin resistance. A reference title mentions inflammation and insulin resistance, but does not establish the claimed mechanism. (LLM, conf=0.76)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although not significant, there was a trend toward a reduction in certain SASP proteins in the serum of patients in the treated group.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > CLINICAL TRIALS
What the sources say
- Partly supportedcites [83] sourceExperimental — accuracy not yet measured
The Results section reports a nonsignificant potential reduction in select circulating SASP proteins in patients with IPF. The claim specifies serum, but the Methods section says the exploratory SASP assays used plasma, and the Results say targeted ELISA did not confirm the IL-6 and MMP7 findings. (LLM, conf=0.85)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“We demonstrated the effectiveness of this approach using greater omental adipose explants resected during surgery (26).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > MODELS FOR PRECLINICAL TESTING OF SENOLYTICS > Human Tissue Explants
What the sources say
- Supportedcites [26] source
The Results (Fig. 4E–F) report that fisetin-treated greater omental adipose explants resected during surgery had significantly fewer senescence-marker-positive cells and lower levels of several SASP factors. The Human adipose tissue explants methods section confirms that the tissue came from three human surgical patients and was treated ex vivo. (LLM, conf=0.92)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“screening for kinases that regulate senescence in human telomerase reverse transcriptase immortalized-retinal pigment epithelial 1 (hTERT-RPE1) cells using siRNA also revealed several key kinases important for regulating senescence, including a target for dasatinib (71).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > APPROACHES TO IDENTIFY SENOLYTICS > Drug Screening
What the sources say
- Partly supportedcites [71] sourceExperimental — accuracy not yet measured
The Results section, “Identification of senescence-inducing kinase siRNAs” (page unavailable), describes an siRNA screen in hTERT-RPE1 cells that identified senescence-like kinase hits; the Introduction reports 12 validated regulators. Our copy does not identify any of those kinases as a dasatinib target, so that part of the claim is unsupported. (LLM, conf=0.86)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“we identified several senescence cell antiapoptotic pathways (SCAPs) (19), including ephrins/dependence receptors; PI3Kδ/AKT/metabolic; BCL-2/BCL-xL/BCL-W; p53/FOXO4a/p21/serpin [plasminogen activator inhibitors 1 and 2 (PAI-1, PAI-2)]; hypoxia-inducible factor 1α (HIF-1α); and the HSP90 pathway.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > APPROACHES TO IDENTIFY SENOLYTICS > Hypothesis-Driven, Mechanism-Based Approach
What the sources say
- Partly supportedcites [19] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“we demonstrated the senolytic activity of D+Q by administering one application of D+Q to mice following hind limb irradiation (19).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > MODELS FOR PRECLINICAL TESTING OF SENOLYTICS
What the sources say
- Supportedcites [19] source
In Results (‘Dasatinib and quercetin reduce senescent cells in vivo’), the paper reports that a single D+Q treatment after irradiation of one mouse leg reduced senescence markers in muscle and fat at the irradiated site. The Results section on treadmill exercise capacity also describes the single treatment and subsequent functional improvement. (LLM, conf=0.94)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Ercc1−/Δ mice spontaneously develop Sncs in multiple tissues as a result of an accumulation of endogenous DNA damage, mitochondrial dysfunction, and increased abundance of reactive oxygen species (72).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > MODELS FOR PRECLINICAL TESTING OF SENOLYTICS > Murine Models
What the sources say
- Partly supportedcites [72] sourceExperimental — accuracy not yet measured
The Results sections on senescent-cell accumulation and elevated ROS report senescence markers in multiple Ercc1−/Δ tissues, alongside endogenous DNA damage and increased ROS. The Results section on ROS production finds altered mitochondrial respiration but says it *could* contribute to ROS production; it does not establish mitochondrial dysfunction as a cause of senescent-cell accumulation. (LLM, conf=0.83)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This BubR1H/H progeria model has accelerated and elevated superphysiologic levels of cellular senescence due to chromosome missegregation as well as increasing aneuploidy (8, 80).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > MODELS FOR PRECLINICAL TESTING OF SENOLYTICS > Murine Models
What the sources say
- Partly supportedcites [8] sourceExperimental — accuracy not yet measured
The main text (page unavailable) describes BubR1H/H mice as progeroid and reports that they selectively accumulate p16Ink4a-positive senescent cells in adipose tissue, skeletal muscle and eye. It identifies BubR1 as part of the checkpoint for accurate chromosome segregation, but does not establish that missegregation or increasing aneuploidy causes the senescence, or quantify it as superphysiologic relative to normal ageing. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [80] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The first senolytic drug reported was D+Q (19).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > APPROACHES TO IDENTIFY SENOLYTICS > Hypothesis-Driven, Mechanism-Based Approach
What the sources say
- Supportedcites [19] source
The Discussion identifies dasatinib and quercetin as the prototype senolytic agents identified in this work. The Results report that their combination, D+Q, selectively killed senescent cells in vitro and reduced senescent-cell markers in mice. Together, these passages support the citing sentence’s characterization of D+Q as the first reported senolytic treatment. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Induction of senescence in hepatocytes results in fat accumulation in vitro and in vivo (15).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Liver
What the sources say
- Supportedcites [15] source
In the Results section, irradiated hepatocyte cultures developed a senescent phenotype and showed increased fat-droplet intensity compared with non-senescent hepatocytes, supporting the in vitro part. The same section reports that hepatocyte-specific loss of Xpg in mice increased senescence markers alongside age-dependent liver fat accumulation, supporting the in vivo part. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The abundance of Sncs in adipose tissue and macrophage infiltration were decreased 11 days after the last of 3 daily doses of D+Q (82).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > CLINICAL TRIALS
What the sources say
- Supportedcites [82] source
The Methods describe an open-label Phase 1 pilot study in people with diabetic kidney disease given three days of oral D+Q, with biopsies taken 11 days after treatment. The Results report reduced adipose-tissue senescent-cell markers and fewer CD68+ macrophages at that follow-up. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A composite score of blood SASP factors was also reduced 11 days after completing the last of the 3 daily doses of D+Q.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > CLINICAL TRIALS
What the sources say
- Partly supportedcites [82] sourceExperimental — accuracy not yet measured
The Results report that several individual plasma SASP factors were significantly lower 11 days after the three-day D+Q course, and the Discussion confirms the timing. The paper does not report a composite score of those blood factors, so that specific measure is unsupported. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“the therapeutic window of navitoclax is improved by utilizing an approach that degrades certain BCL-2 family members instead of just inhibiting their function (76).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > APPROACHES TO IDENTIFY SENOLYTICS > Senolytic Optimization
What the sources say
- Supportedcites [76] source
The Abstract says the authors converted navitoclax (ABT263) into DT2216, a PROTAC that degrades BCL-XL, and found it more potent against BCL-XL-dependent cancer cells but less toxic to platelets. The Discussion likewise describes the navitoclax-derived degrader as safer and more effective than the original inhibitor. (LLM, conf=0.90)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“We have used medicinal chemistry to increase the therapeutic window of several senolytic compounds.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > APPROACHES TO IDENTIFY SENOLYTICS > Senolytic Optimization
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“That single administration conferred a therapeutic benefit in terms of treadmill performance that endured for over 1 year.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > MODELS FOR PRECLINICAL TESTING OF SENOLYTICS
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“By passage 5 at 21% O2, roughly half of the MEFs are SA-βgal positive”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > APPROACHES TO IDENTIFY SENOLYTICS > Drug Screening
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Results of the trial using UBX0101 to treat osteoarthritis have been disappointing to date”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > CLINICAL TRIALS
What the sources say
- Not matchedcites https://clinicaltrials.gov/ct2/show/NCT04229225
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Alvespimycin (17-DMAG) and other HSP90 inhibitors were also found to be senolytic.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > APPROACHES TO IDENTIFY SENOLYTICS > Drug Screening
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Since 2015, several senolytics went from identification to clinical trial.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Evidence suggests that the role of the SASP is to entice immune clearance.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Cellular Senescence
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, Sncs appear to play a major role in driving life-limiting age-related diseases.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Cellular Senescence
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“However, with age, an increasing dysfunctional immune system contributes to an accumulation of Sncs.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Cellular Senescence
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“All these drugs extend health span in mice, illustrating the utility of senomorphic approaches.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“As a result, Sncs accumulate abundantly in adipose tissue of aging and obese humans and mice.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Adipose Tissue
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“One of the key challenges in senescence research is the lack of biomarkers that unambiguously discriminate Sncs from non-Sncs, particularly in vivo.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > MEASURING SENESCENCE
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Following skeletal muscle injury in young mice, transplanted satellite cells from geriatric mice are unable to become activated and proliferate.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Skeletal Muscle
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“by altering local paracrine signaling from senescent endothelial and inflammatory cells in cardiovascular microenvironments, including reduced nitric oxide bioavailability and impaired endothelial function (which are strong predictors of all-cause mortality) (61)”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Cardiovascular System
What the sources say
- Not checked — no full text of the sourcecites [61] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Diet-induced obesity contributes to early memory impairment and amyloid-β or tau neuropathology in mouse models of AD (60).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Brain
What the sources say
- Not checked — no full text of the sourcecites [60] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“The percentage of senescent osteocytes in bone cortices in old mice is approximately sixfold higher than that in young mice, as measured by SADS.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Bone
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Sncs accumulate in glial cells and neurons in different brain regions of both obese and aged mice.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Brain
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, the accumulation of Sncs in adipose tissue appears to be a causal factor in ageand obesity-related inflammation and metabolic derangements.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Adipose Tissue
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Recent studies demonstrated that Sncs accumulate with age in the mouse brain, as measured by expression of TAFs and p21Cip1.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Brain
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Emerging data suggest the increased Snc burden influences age-associated cardiovascular dysfunction via three major mechanisms: (a) by augmenting known risk factors for cardiovascular disease, including systemic inflammation, type 2 diabetes, and subsequent hyperglycemia”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Cardiovascular System
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“which suggests that Sncs play an important role in cardiovascular morbidity and mortality.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Cardiovascular System
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These findings suggest that within the bone microenvironment, senescent osteocytes and senescent myeloid cells may be the key producers of the SASP.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Bone
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Human aging is associated with decreased expression of BUBR1 in multiple tissues (80).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > MODELS FOR PRECLINICAL TESTING OF SENOLYTICS > Murine Models
What the sources say
- Not checked — no full text of the sourcecites [80] source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The senolytic activity of D+Q, fisetin, navitoclax, and other molecules was confirmed in the MEF assay.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > APPROACHES TO IDENTIFY SENOLYTICS > Drug Screening
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These studies suggest that elimination of Sncs may be a therapeutic strategy to alleviate NAFLD.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Liver
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Eliminating senescent cells by genetic ablation of p16Ink4a-expressing cells or by D+Q reduces hepatic steatosis.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“This mechanism-based, hypothesis-driven approach led to the identification of more senolytic drugs, including fisetin and related natural products, other BCL-2 family inhibitors A1331852 and A1155463.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > APPROACHES TO IDENTIFY SENOLYTICS > Hypothesis-Driven, Mechanism-Based Approach
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This result strongly suggests that D+Q decreases the Snc burden in humans.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > CLINICAL TRIALS
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Taken together, however, these early results suggest that senolytic agents hold promise for treating age-related disease.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > CLINICAL TRIALS
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This finding is consistent with a hit-and-run mechanism in which the drug kills disease-causing cells, characteristic of senolytics, rather than inhibiting a molecular target, which requires continuous exposure to the therapeutic.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > MODELS FOR PRECLINICAL TESTING OF SENOLYTICS
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“More rigorous approaches, such as the injection of labeled Sncs followed by drug treatment, document that senolytic function in vivo is similar to that in vitro, killing that specific type of transplanted Snc.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > MODELS FOR PRECLINICAL TESTING OF SENOLYTICS
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Simply measuring a reduction in markers of senescence, such as cell cycle regulators, SASP factors, or SA-βgal activity, in a tissue does not necessarily prove that Sncs are being eliminated.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > MODELS FOR PRECLINICAL TESTING OF SENOLYTICS
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 61
- Probably not a substantial claim. 4
- The quote only partly states this claim. 1
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The use of a navitoclax PROTAC facilitated the rapid and specific degradation of BCL-2, resulting in apoptosis of cancer cells with less off-target lysis.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > APPROACHES TO IDENTIFY SENOLYTICS > Senolytic Optimization
What the sources say
- Disputedcites [76] sourceExperimental — accuracy not yet measured
The Discussion states that DT2216, the PROTAC derived from navitoclax, is specific for BCL-XL and does not induce BCL-2 degradation. The Abstract supports reduced platelet toxicity and antitumor activity, but explicitly says DT2216 does not degrade BCL-2—the central target named in the claim. (LLM, conf=0.94)
Checked by a reasoning model — may be wrong.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Old age is the greatest risk factor for the chronic diseases responsible for the majority of morbidity, mortality, and health-care costs worldwide (1, 2).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Geroscience Hypothesis
What the sources say
- Partly supportedcites [1] sourceExperimental — accuracy not yet measured
The Abstract calls aging the greatest risk factor for a majority of chronic diseases driving morbidity and mortality. The Aging Research Initiative says chronic diseases account for the majority of global disease burden and are the most common causes of mortality. It calls them a major global healthcare burden, but does not establish that they account for the majority of healthcare costs worldwide. (LLM, conf=0.86)
- Partly supportedcites [2] sourceExperimental — accuracy not yet measured
The indexed Abstract (page not provided) calls aging the primary risk factor for major human pathologies, including cancer, diabetes, cardiovascular disorders, and neurodegenerative diseases. It does not say that these diseases account for the majority of morbidity, mortality, and health-care costs worldwide. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Fisetin reduces senescence in aged nonhuman primates and human tissue explants (26).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
What the sources say
- Partly supportedcites [26] sourceExperimental — accuracy not yet measured
The Results report reduced senescence markers in human adipose tissue explants treated with fisetin. The animal experiments described in the Abstract (Methods) and Results used aged mice, not aged nonhuman primates, so the primate part of the claim is unsupported. (LLM, conf=0.91)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Currently, it is accepted that there is not one single biomarker of Sncs (Figure 2) and that only through the simultaneous measure of multiple end points can Sncs be identified accurately (30).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > MEASURING SENESCENCE
What the sources say
- Supportedcites [30] source
The in vivo identification section states that no single marker has absolute specificity for senescent cells and advises a multi-marker approach for more robust detection. The Figure 3 workflow specifies co-staining with additional markers and says the multi-marker workflow can identify senescent cells with the highest accuracy. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Inhibitors of these prosurvival proteins, often using repurposed cancer chemotherapeutics, kill Sncs (senolysis), leading to the creation of the first senolytic drugs (19).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
What the sources say
- Partly supportedcites [19] sourceExperimental — accuracy not yet measured
The Discussion (page not provided) calls dasatinib and quercetin prototype senolytic agents and says targeting pro-survival mechanisms selectively clears senescent cells. The Results, “Candidate senolytic drugs in vitro” (page not provided), identifies dasatinib as a cancer treatment but quercetin as a natural flavonol; it does not establish that repurposed cancer chemotherapeutics are often used for this purpose. (LLM, conf=0.86)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Rapamycin, an immunosuppressant, decreases the SASP and maintains cell cycle arrest but does not kill Sncs (24).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
What the sources say
- Supportedcites [24] source
The Results sections “Rapamycin decreases the SASP” and “Rapamycin does not reverse cellular senescence” report that rapamycin selectively reduced SASP factors without reversing growth arrest in the primary human cells tested. Senescent-cell numbers were unchanged after treatment, supporting the statement that rapamycin did not kill those cells. (LLM, conf=0.91)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Fisetin extends the health span and life span of mice and reverses tissue damage when administered to aged animals (26).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
What the sources say
- Partly supportedcites [26] sourceExperimental — accuracy not yet measured
The Discussion reports improved healthspan and extended lifespan in mice treated late in life. The Results report reduced age-related pathology and improved tissue homeostasis in aged mice, but compare treated mice with controls rather than demonstrating that pre-existing tissue damage was reversed. (LLM, conf=0.84)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Clearance of Sncs in INK-ATTAC or p16-3MR mice restores vascular reactivity (12), stabilizes atherosclerotic plaques (13), improves pulmonary function (14), alleviates osteoarthritis (10), improves fatty liver disease (15), improves lung function in a pulmonary fibrosis model (14), and prevents age-related bone loss (16).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Cellular Senescence
What the sources say
- Supportedcites [12] sourceExperimental — accuracy not yet measured
This source is cited for the vascular-reactivity clause, not the other conditions, which have separate citations. In the age-related vascular pathology section (page unavailable), the paper reports improved carotid-artery relaxation after senescent-cell clearance and similar effects following genetic clearance in INK-ATTAC mice. (LLM, conf=0.91)
- Partly supportedcites [13] sourceExperimental — accuracy not yet measured
For citation (13), the paper reports that clearing senescent cells in mice improved fibrous-cap thickness, collagen content, and other surrogate markers of plaque stability (section labeled Abstract; page not provided). It concludes that these results strongly suggest greater plaque stability, but it does not establish plaque stabilization through observed rupture outcomes. The other conditions in the sentence are attached to different citations and are not assessed here. (LLM, conf=0.84)
- Supportedcites [14] sourceExperimental — accuracy not yet measured
The Abstract and Discussion report that genetic clearance of p16-positive cells in Ink-Attac mice improved pulmonary function after bleomycin-induced lung injury. This supports the pulmonary-function and pulmonary-fibrosis-model claims attached to citation (14); the other conditions in the sentence have separate citations. (LLM, conf=0.92)
- Supportedcites [15] sourceExperimental — accuracy not yet measured
The citation to this paper is attached to the fatty-liver claim, not the other listed conditions. In Results, “Senescent cell clearance decreases liver fat accumulation,” the paper reports that AP-induced elimination of senescent cells in INK-ATTAC mice significantly reduced hepatic fat deposition in aged mice and mice fed a high-fat diet. (LLM, conf=0.93)
- Supportedcites [16] sourceExperimental — accuracy not yet measured
The citation to this paper is attached specifically to the claim that senescent-cell clearance prevents age-related bone loss, not to the other conditions listed. The paper’s Abstract reports that genetic clearance using INK-ATTAC in old mice with established bone loss improved bone mass, strength, and microarchitecture relative to controls. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, a peptide that blocks the interaction of p53 with FOXO4 (a forkhead transcription factor family member that binds p53 to induce cellular senescence) induces apoptosis of Sncs in vitro and in vivo, improving fitness, hair growth, and renal function in progeroid and aged mice (29).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
What the sources say
- Supportedcites [29] source
The Results report that FOXO4-DRI competes with FOXO4 for p53 binding and induces caspase-dependent apoptosis in senescent cells in vitro. The in vivo Results report reduced senescence and improved fur density, activity or responsiveness, and renal function in fast-aging and naturally aged mice; apoptosis was also observed in treated aged kidney slices ex vivo. Page numbers were not available in our copy. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Treating mice with navitoclax reduces Snc burden, alleviates radiation-induced hematopoietic stem cell dysfunction (28), and improves osteoarthritis (10).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
What the sources say
- Supportedcites [28] source
The paper’s Abstract (page unavailable) reports that ABT263 cleared senescent cells in mice and improved the function of irradiated hematopoietic stem cells. The osteoarthritis statement has a separate citation (10) in the citing sentence, so it is not attributed to this paper. (LLM, conf=0.92)
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The paper’s osteoarthritis results (Fig. 2 and Supplementary Fig. 3; page unavailable) report reduced senescent cells, pain, and cartilage erosion in mice treated with UBX0101. The Online Methods list UBX0101, ganciclovir, and AP20187 as treatments, not navitoclax, so this source does not support attributing the osteoarthritis improvement to navitoclax. The radiation-induced stem-cell claim is attached to citation (28), not this source’s citation (10). (LLM, conf=0.86)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Sncs are heterogeneous for several reasons. First, senescence is a dynamic, not static, process. Thus, it is reasonable to assume that within a tissue both early and late Sncs coexist and have distinct phenotypes. Second, Sncs have different expression profiles based on their cell lineage as well as the type of stress that triggered senescence (31). Finally, Sncs play different roles depending on”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > MEASURING SENESCENCE > Multiple Markers of Senescence
What the sources say
- Supportedcites [31] source
Citation (31) is attached to the claim that expression profiles differ by cell lineage and senescence-inducing stress. The Abstract reports transcriptome signatures specific to senescent cell types and inducing stresses; the Results and Discussion also describes cell-type-dependent gene expression. The surrounding claims about timing and physiological roles are not attached to this citation. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“D+Q also reduces aortic calcification of atherosclerotic ApoE−/− mice (12), improves lung function in a murine model of idiopathic pulmonary fibrosis (14), reduces hepatic steatosis (15), and prevents age-related bone loss (16).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
What the sources say
- Supportedcites [12] source
The citation to this paper (12) supports only the aortic-calcification clause; the other outcomes have separate citations. In “Can chronic senolytic treatment improve hypercholesterolemia-induced vascular pathology?” the paper identifies the mice as ApoE−/− and reports significantly less intimal plaque calcification with D+Q than with vehicle (Fig. 2I). (LLM, conf=0.95)
- Supportedcites [14] source
The Results section (‘Senescent cell clearance mitigates fibrotic lung disease’) reports that dasatinib plus quercetin diminished impaired airway function and reduced the loss of lung compliance in bleomycin-injured mice. The paper identifies bleomycin-induced lung injury as its mouse model of idiopathic pulmonary fibrosis. The other effects in the citing sentence have separate citations and are not attributed to this source. (LLM, conf=0.94)
- Supportedcites [15] source
Citation (15) supports only the hepatic-steatosis part of the sentence. In Results, “Senescent cell clearance decreases liver fat accumulation,” the paper reports a significant reduction in hepatic fat deposition after D+Q treatment in aged mice and reduced liver fat accumulation in diabetic db/db mice. (LLM, conf=0.94)
- Supportedcites [16] source
Citation (16) is attached specifically to the age-related bone-loss claim, not to the preceding claims about aortic calcification, lung function, or hepatic steatosis. In the supplied Abstract passages, monthly D+Q treatment of old mice improved trabecular bone microarchitecture, cortical thickness, and bone strength relative to vehicle. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several senolytics target prosurvival pathways, including the BCL-2/BCL-xL, p53/p21, and PI3K/AKT, and the antiapoptotic pathways, including serpins.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
What the sources say
- Partly supportedcites [19] sourceExperimental — accuracy not yet measured
The Results (Senolytic siRNAs) identify BCL-xL, p21, PI3KCD and the serpin PAI-2 as senolytic targets; the Results (Candidate senolytic drugs in vitro) describe quercetin as inhibiting PI3K and serpins. But the Discussion proposes p53 and AKT as targets for future senolytics rather than showing that tested senolytics target them, and these passages do not establish BCL-2 as a target. Page numbers are not available in our copy. (LLM, conf=0.85)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Note that Sncs are not always pathological. They play important roles in, for example, wound healing and parturition (23).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
What the sources say
- Partly supportedcites [23] sourceExperimental — accuracy not yet measured
The Introduction and Discussion (page unavailable) report that senescent cells promote cutaneous wound healing, supporting the point that they are not always harmful. Our copy does not address a role in parturition (searched: parturition, childbirth), so that example is unsupported by this source. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A key study demonstrating that caloric restriction, which increases health span and life span, decreases the accumulation of Sncs (18)”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
What the sources say
- Partly supportedcites [18] sourceExperimental — accuracy not yet measured
In “Caloric restriction retards p16 INK4a accumulation” (page not provided), the paper reports that caloric restriction abolished an age-related increase in a senescence marker in mouse and rat kidneys. It also reduced age-related Ink4a/Arf expression in some tissues, but not others. The study measured markers rather than directly counting senescent cells, so it does not establish a general decrease in their accumulation. (LLM, conf=0.88)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Ablating p16+ cells in these mice suppresses age-related disease, extending the health span of two independent strains of transgenic mice: INK-ATTAC and p16-3MR (see Supplemental Figure 1 for a description of the models) (8–10).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Cellular Senescence
What the sources say
- Partly supportedcites [8] sourceExperimental — accuracy not yet measured
The main text reports that clearing p16-positive cells delayed selected age-related deficits and preserved function in BubR1 progeroid mice carrying INK-ATTAC. Its two tested transgenic lines were INK-ATTAC-3 and INK-ATTAC-5, not INK-ATTAC and p16-3MR; our copy does not report a p16-3MR experiment. No page number is available in the indexed copy. (LLM, conf=0.90)
- Partly supportedcites [9] sourceExperimental — accuracy not yet measured
The Abstract and “p16 Ink4a-positive cells shorten lifespan and healthspan” report that clearing p16-positive cells in INK-ATTAC mice extended median lifespan and attenuated age-related deterioration. The two cohorts had different genetic backgrounds, but both used ATTAC; the paper mentions p16-3MR in cell-culture and model-comparison material, not as a second mouse model in which it demonstrated these healthspan effects. Page numbers were not provided for these passages. (LLM, conf=0.90)
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The main text (Fig. 3a–c) reports that clearing p16-positive cells in INK-ATTAC mice reduced age-related cartilage degeneration. It also reports reduced post-traumatic osteoarthritis symptoms in p16-3MR mice (Fig. 1), but does not show extended health span in both strains; its statement about increased healthy lifespan cites earlier work. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senomorphics are aimed largely at suppressing the SASP and thereby inflammation.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
What the sources say
- Partly supportedcites [20] sourceExperimental — accuracy not yet measured
The Discussion defines senomorphics as compounds that suppress senescent phenotypes, and the Introduction identifies the SASP as including pro-inflammatory factors. But the paper does not say that suppressing the SASP—and thereby inflammation—is the main aim of senomorphics; it describes their action more broadly. (LLM, conf=0.84)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senolytics do clear postmitotic cells with senescent features, resulting in beneficial health outcomes (16, 34, 35) and reinforcing Sncs’ role in causing disease.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > MEASURING SENESCENCE > Multiple Markers of Senescence
What the sources say
- Supportedcites [16] source
The paper describes terminally differentiated, non-dividing cells as capable of senescence and reports that senolytic D+Q treatment reduced the percentage of senescent osteocytes in old mice (main text, indexed under Abstract; no page supplied). It also reports improved bone outcomes and concludes that senescent cells play a causal role in age-related bone loss in mice. The demonstrated health benefit and causal finding are specific to bone loss in mice. (LLM, conf=0.90)
- Partly supportedcites [34] sourceExperimental — accuracy not yet measured
The Introduction and Discussion report that clearing senescent cells in obese mice alleviated impaired neurogenesis and anxiety-like behavior, supporting a disease-contributing role for those cells. But the paper identifies the affected cells as senescent glia, not specifically as postmitotic cells; the Results also say treatment did not alter the frequency of mature neurons. Thus the postmitotic-cell part of the claim is not established by this source. (LLM, conf=0.84)
- Supportedcites [35] source
The Results section, “Senescent-cell clearance reduces cardiac hypertrophy and fibrosis,” reports that the senolytic navitoclax selectively killed senescent cardiomyocytes in vitro and reduced hypertrophy and fibrosis in aged mice. The Discussion describes post-mitotic cardiomyocyte senescence as an effector of myocardial ageing. These findings support the cited sentence as an example involving post-mitotic cells; the reported benefit is improved cardiac-ageing features, not a significant improvement in measured cardiac function. (LLM, conf=0.86)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Dasatinib plus quercetin (D+Q) extends health span and life span in aged mice (17), improving cardiovascular function and treadmill endurance, while decreasing frailty, neurologic dysfunction, and bone loss in mice (19).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
What the sources say
- Supportedcites [17] source
The Abstract states that senolytics enhanced remaining health- and lifespan in old mice. The Results section on aged mice reports improved physical function after D+Q treatment and a 36% higher median post-treatment lifespan. The cardiovascular, frailty, neurologic, and bone-loss claims are attached to a different citation in the printed sentence and are not judged here. (LLM, conf=0.93)
- Supportedcites [19] source
The Results report improved cardiovascular function in 24-month-old mice, greater treadmill endurance in irradiated mice, and reduced frailty and neurologic symptoms with improved bone parameters in progeroid mice (pages not provided). The life-span statement is attached to citation (17), not this source’s citation (19). (LLM, conf=0.91)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Genetic clearance of p16-expressing Sncs from old INK-ATTAC mice results in a 46% reduction in senescent osteocytes, as assessed by measuring SADS, and significantly improves trabecular bone, thicker cortices, and bone strength in the spine and femur (16).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Bone
What the sources say
- Supportedcites [16] source
The paper’s account of the INK-ATTAC experiment reports 46% fewer SADS-positive senescent osteocytes after AP20187 treatment. It also reports better trabecular bone microarchitecture at the spine and femur, significantly greater femoral cortical thickness and strength, and significantly better vertebral biomechanical properties. The copy provides no page number for these passages. (LLM, conf=0.91)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“and hepatocellular carcinoma (65).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Liver
What the sources say
- Partly supportedcites [65] sourceExperimental — accuracy not yet measured
The Abstract and Discussion link chronic liver inflammation and neutrophil-driven damage to hepatocellular carcinoma. The Discussion also mentions increased cellular senescence in the liver, but the paper does not establish that a senescence-associated secretory phenotype (SASP) drives the inflammation or spreads senescence among hepatocytes. Page numbers are unavailable in our copy. (LLM, conf=0.84)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Sncs contribute to chemoattraction of immune cells to visceral adipose tissue in obesity, further contributing to insulin resistance and risk of diabetes (41).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Adipose Tissue
What the sources say
- Supportedcites [41] source
The Cellular senescence section states that senescent cells attract macrophages to visceral adipose tissue in obesity and can directly cause insulin resistance. The same section links increased senescent-cell burden to type 2 diabetes risk. Page numbers were not supplied in our copy. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Interventions that reduce Snc burden can dramatically attenuate arterial calcification, improve endothelial function and nitric oxide signaling (12), and improve survival after major cardiovascular insults”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Cardiovascular System
What the sources say
- Supportedcites [12] source
The Abstract reports improved vasomotor function and nitric oxide responses after senolytic treatment in aged and hypercholesterolemic mice. It reports significantly reduced calcification in hypercholesterolemic mice, while calcification in aged mice only tended to decline. The survival phrase follows citation (12) and is not attributed to this source. (LLM, conf=0.90)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Expression of SASP factors, as measured by quantitative polymerase chain reaction (qPCR), is significantly increased in osteocytes but not in osteoblast progenitors or osteoblasts (45).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Bone
What the sources say
- Supportedcites [45] source
The Results report rt-qPCR measurements of SASP genes in the cell populations. In old versus young mice, 23 of 36 genes were significantly higher in osteocytes, while relatively few changed significantly in osteoblast progenitors or osteoblasts; the latter groups showed no significant overall gene-set change. The claim accurately summarizes that contrast. (LLM, conf=0.91)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Activin A, a transforming growth factor-β (TGF-β) family member that is a component of the senescent adipocyte progenitor SASP (11), is increased in obese mice and correlates with levels of p16Ink4a.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Adipose Tissue
What the sources say
- Supportedcites [11] source
The citation (11) is attached to the description of activin A as a TGF-β-family member and a component of the senescent fat-progenitor secretory phenotype, not to the subsequent statement about obese mice or p16Ink4a. The Introduction and Results (pages not specified in our copy) identify activin A as a transforming growth factor superfamily member secreted by senescent fat progenitors and discuss it among candidate SASP factors. (LLM, conf=0.92)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Telomere dysfunction, a major driver of hepatocyte senescence, impairs liver regeneration and induces liver cirrhosis in mice (63).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Liver
What the sources say
- Could not verifycites [63] Rudolph D, 2000, Genes Dev sourceExperimental — accuracy not yet measured
The Abstract and “Liver degeneration in NEMO/IKKγ-deficient embryos” section describe embryonic liver apoptosis following NEMO/IKKγ deficiency. Searches for telomere dysfunction, hepatocyte senescence, liver regeneration, and cirrhosis found no passage in our copy addressing the attributed claim. (LLM, conf=0.76)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Activin A impedes expression of the insulin-sensitizing adipogenic transcription factors peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT-enhancer-binding protein α (C/EBPα), thereby contributing to failed adipogenesis, lipotoxicity, and insulin resistance (11).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Adipose Tissue
What the sources say
- Partly supportedcites [11] sourceExperimental — accuracy not yet measured
The Results section, “Inhibition of activin A rescues impaired adipogenesis due to senescent CM” (page unavailable), reports that neutralizing activin A improves adipogenesis. The Introduction and Discussion report increased PPARγ and C/EBPα expression, reduced lipotoxicity, and improved insulin sensitivity after senescent-cell clearance or JAK inhibition. They do not establish that activin A directly blocks those transcription factors or causes the downstream metabolic effects; the Discussion calls the link from impaired adipogenesis to insulin resistance a speculation and notes other possible mechanisms. (LLM, conf=0.86)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“chronic inflammation driven by the SASP spreads hepatocyte senescence, contributing to liver fibrosis (64)”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Liver
What the sources say
- Partly supportedcites [64] sourceExperimental — accuracy not yet measured
The Results sections on cellular senescence and inflammation in vivo report SASP-associated bystander effects in fibroblast experiments and increased hepatocyte senescence in chronically inflamed mouse livers. The Discussion describes SASP signalling as a way senescence may spread to bystander cells. The paper does not establish that SASP spreads senescence specifically between hepatocytes or that this process contributes to liver fibrosis; the liver outcome it reports is impaired regeneration. (LLM, conf=0.84)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senolytics reduce adipocyte hypertrophy, increase the ratio of subcutaneous to visceral adipose tissue, decrease HbA1c, improve glucose tolerance, enhance insulin sensitivity, lower circulating inflammatory mediators, and promote adipogenesis in obese mice (34).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Adipose Tissue
What the sources say
- Partly supportedcites [34] sourceExperimental — accuracy not yet measured
The Results section, under “Pharmacological and Pharmacogenetic Senolytic Approaches Reduce Senescent Cell Burden and Alleviate Systemic Inflammation” (page unavailable), reports that senolytic treatment reduced circulating cytokines in obese mice. Our copy does not report reduced adipocyte hypertrophy, a higher subcutaneous-to-visceral fat ratio, lower HbA1c, improved glucose tolerance or insulin sensitivity, or increased adipogenesis; searches for those outcomes returned no supporting passage. (LLM, conf=0.90)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This concept is supported by a study of aged mice demonstrating that pharmacologic inhibition of the JAK pathway, which regulates the SASP in senescent preadipocytes and endothelial cells in vitro, suppresses markers of both adipose tissue and systemic inflammation and improved parameters of muscle strength, endurance, and coordination (39).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Skeletal Muscle
What the sources say
- Supportedcites [39] source
The systemic and adipose inflammation section reports reduced serum cytokines and adipose inflammatory markers after JAK inhibitor treatment in old mice (Fig. 7). The physical-activity section reports improved grip strength, hanging endurance, and coordination (Fig. 8). The Discussion also reports SASP suppression in senescent preadipocytes and endothelial cells in vitro. (LLM, conf=0.94)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“senescence occurs rapidly when the cells are grown at atmospheric oxygen (O2) as a consequence of unrepaired oxidative DNA damage, which is a physiologically relevant driver of senescence in vivo (72).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > APPROACHES TO IDENTIFY SENOLYTICS > Drug Screening
What the sources say
- Partly supportedcites [72] sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that unrepaired endogenous nuclear DNA damage in Ercc1−/Δ mice causes senescent cells to accumulate more rapidly in vivo, and the Introduction reports increased oxidative DNA damage in those mice. But the cited paper does not establish the claim about rapid senescence in primary DNA-repair-deficient MEFs grown at atmospheric oxygen; searches for MEFs and atmospheric oxygen did not find that result. (LLM, conf=0.87)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The rat closely recapitulates human physiology and pathophysiology and can be used to study aspects of aging, including longevity, senescence-related pathology, and pharmacologic changes with increasing age.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > MODELS FOR PRECLINICAL TESTING OF SENOLYTICS > Rat Models
What the sources say
- Partly supportedcites [81] sourceExperimental — accuracy not yet measured
The review’s Abstract presents rats as a model of human aging and describes their use in studying longevity, age-related pathology, and physiological effects of interventions. Its “Similarity to Human Age-Related Pathology” passage also discusses pharmacological interventions, but does not establish that rats closely recapitulate human physiology and pathophysiology or specifically address how pharmacologic responses change with age. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The Ercc1−/Δ mouse has reduced expression of the ERCC1-XPF endonuclease, which is important for multiple types of DNA repair (78).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > MODELS FOR PRECLINICAL TESTING OF SENOLYTICS > Murine Models
What the sources say
- Supportedcites [78] source
Section 4.5 identifies Ercc1−/Δ mice as hypomorphic for ERCC1-XPF, and the Introduction describes mouse models with decreased levels of the complex. The Introduction also says ERCC1-XPF participates in nucleotide excision repair, interstrand-crosslink repair, and repair of some double-strand breaks. No page numbers are available in our copy. (LLM, conf=0.86)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“navitoclax eliminates only a restricted range of Sncs and is not senolytic against, for example, human adipocyte progenitors, one of the most abundant Snc types in aged humans or in diabetes and obesity (27), and is not senolytic against human astrocytes.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > APPROACHES TO IDENTIFY SENOLYTICS > Further Development of Senolytics
What the sources say
- Partly supportedcites [27] sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says navitoclax targets a limited range of senescent cell types and is not senolytic against senescent human primary preadipocytes, supporting the claim about adipocyte progenitors. The paper does not report testing human astrocytes, so it does not support that part of the claim. (LLM, conf=0.89)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“we and others reported that navitoclax, a BCL-2 family inhibitor, is senolytic in some but not all Snc types (26).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > APPROACHES TO IDENTIFY SENOLYTICS > Hypothesis-Driven, Mechanism-Based Approach
What the sources say
- Supportedcites [26] source
The Introduction states that navitoclax targets BCL-2 pro-survival pathway members and causes apoptosis in some but not all senescent cell types. It also says navitoclax decreases the abundance of some but not all human and mouse senescent cell types in vitro. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Physical function such as gait speed and chair stand time improved in the treated group.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > CLINICAL TRIALS
What the sources say
- Supportedcites [83] source
The Results (Functional and biological measures) report significant improvements in 4-m gait speed and chair-stands after DQ treatment. The Discussion describes the study as a single-arm, open-label pilot conducted at two clinical sites. The claim reports improvement within the treated group, not an effect relative to a control group. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Compared with mouse physiology, rat physiology is easier to monitor and in general more similar to that of humans (81).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > MODELS FOR PRECLINICAL TESTING OF SENOLYTICS > Rat Models
What the sources say
- Partly supportedcites [81] sourceExperimental — accuracy not yet measured
The Abstract says rats’ larger size makes physiological analyses, catheterization, and repeated blood sampling easier than in mice. Its glucose-clamp table also shows rat values closer to human values than mouse values for the measures listed. Those specific comparisons do not establish the broader claim that rat physiology is generally more similar to human physiology. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Aged wild-type mice and progeroid Ercc1−/Δ mice accumulate Sncs in the same tissues and to the same level (79), making Ercc1−/Δ mice a good model for studying senolysis.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > MODELS FOR PRECLINICAL TESTING OF SENOLYTICS > Murine Models
What the sources say
- Supportedcites [79] source
The Discussion reports that aged wild-type and progeroid Ercc1−/Δ mice develop senescent cells in the same tissues and at similar levels, although accumulation is faster in the progeroid mice. It concludes that Ercc1−/Δ mice offer a rapid model for evaluating senotherapeutics, which supports their use in studying senolysis. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“SCAPs differ between cell types; for example, senescent adipocyte progenitors do not depend on BCL-2 family proteins, whereas senescent HUVECs depend on BCL-xL, PI3K, and the HIF-1α pathways.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > APPROACHES TO IDENTIFY SENOLYTICS > Hypothesis-Driven, Mechanism-Based Approach
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“screening a library of drugs that regulate autophagy identified rapamycin and rapamycin derivatives known as rapalogs as senomorphic and the HSP90 inhibitors geldanamycin and tanespimycin (17-AAG) as senolytic.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > APPROACHES TO IDENTIFY SENOLYTICS > Drug Screening
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, they are regarded as a logical therapeutic target.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Senotherapeutics are a new class of drugs that selectively kill Sncs (senolytics) or suppress their disease-causing phenotypes (senomorphics/senostatics).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Sncs accumulate with age and at anatomical sites of disease.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Preclinical data indicate that senolytics alleviate disease in numerous organs, improve physical function and resilience, and suppress all causes of mortality, even if administered to the aged.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > Abstract
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Senescent cells (Sncs) often develop a senescence-associated secretory phenotype to prompt immune clearance, which drives chronic sterile inflammation and plays a causal role in aging and age-related diseases.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In addition, metformin, a drug widely used to treat type 2 diabetes, limits NF-κB activation (25), thereby reducing the SASP.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
What the sources say
- Not checked — no full text of the sourcecites [25] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The SASP also has negative effects on stem cell function, leading to impaired tissue regeneration (Figure 1).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Cellular Senescence
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Sncs are found at anatomical sites of many diseases (see the list in the Supplemental Appendix) and play a causal role in pathology.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Cellular Senescence
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Even a relatively low number of Sncs are sufficient to cause a chronic, sterile inflammation that disrupts tissue homeostasis and reduces resilience to stress, termed inflammaging (Figure 1).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Cellular Senescence
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, no senotherapeutic approach should interfere with pathways controlling the cell cycle or the mechanisms driving senescence, as this could promote cancer.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Senolytics and senomorphics do not interfere with Snc generation, allowing Sncs to form as needed to arrest damaged cells.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > INTRODUCTION > Senotherapeutics
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Elimination of Sncs also prevents migration of transplanted monocytes into intra-abdominal adipose tissue and reduces the number of macrophages in this tissue.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Adipose Tissue
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Importantly, clearance of Sncs, by either genetic or pharmacologic approaches, restores neurogenesis and significantly decreases obesity-induced anxiety-like behavior.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Brain
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“This accumulation is associated with increased activity of SA-βgal and expression of PAI-1, p53, and p16INK4a in adipose tissue and contributes to reduced adipogenesis.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Adipose Tissue
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“p53 activation, as occurs in senescence, also inhibits adipocyte differentiation, blunts insulin-induced glucose transport, and increases lipolysis in adipocytes, further contributing to both inflammation and insulin resistance.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Adipose Tissue
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, Sncs increase with age in bones of mice and contribute to osteoporosis, suggesting that senolytics might prove useful to treat this disease and prevent the risk of fractures in the elderly.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Bone
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Correspondingly, systemic elimination of p16-expressing cells in INK-ATTAC mice, or elimination of Sncs through administration of senolytic drugs, modestly improves measures of physical function in older mice.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Skeletal Muscle
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Targeted repression of p16Ink4a, however, restores satellite cell activation in vitro and augments stem cell engraftment and self-renewal in injured tissue in vivo.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Skeletal Muscle
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“by promoting redifferentiation of local cells to osteoblast-like or synthetic cell phenotypes (62), both of which favor matrix disruption and excess/alternate matrix production and are mechanistic contributors to vascular stiffening, hypertension, and resultant end-organ failure.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Cardiovascular System
What the sources say
- Not checked — no full text of the sourcecites [62] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In addition, microalbuminuria is decreased and renal podocyte and cardiac diastolic function are improved with senolytic therapy.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > EVIDENCE THAT SENESCENCE DRIVES AGING AND AGE-RELATED DISEASES > Adipose Tissue
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When prosurvival networks instead of single molecules are targeted, specificity for Sncs can be increased, side effect profiles flattened, and off-target effects on non-Sncs reduced.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > APPROACHES TO IDENTIFY SENOLYTICS > Further Development of Senolytics
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“All are effective orally and their elimination t½ is less than 4 h (73, 74)”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > APPROACHES TO IDENTIFY SENOLYTICS > Further Development of Senolytics
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The BubR1H/H mice are also progeroid and carry two hypomorphic alleles of the BUB1B gene, which encodes a core component of the mitotic spindle assembly checkpoint (BUBR1) (80).”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > MODELS FOR PRECLINICAL TESTING OF SENOLYTICS > Murine Models
What the sources say
- Not checked — no full text of the sourcecites [80] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“certain senolytics may be cell-type specific or tissue specific, so it will be important to examine multiple tissue and cell types for effects.”
§ Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span > MODELS FOR PRECLINICAL TESTING OF SENOLYTICS
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
The paper relies on this without support.
Findings about senescent cells and senolytic drugs in mice are predictive of human aging and human disease outcomes.
“Thus, Sncs increase with age in bones of mice and contribute to osteoporosis, suggesting that senolytics might prove useful to treat this disease and prevent the risk of fractures in the elderly.”
“These preclinical studies of numerous different drugs targeting Sncs via a variety of mechanisms illustrate the tremendous potential of senotherapeutics.”
The paper relies on this without support.
The health benefits seen after senolytic treatment are caused by removal of senescent cells rather than by unrelated drug effects.
“Senolytics do clear postmitotic cells with senescent features, resulting in beneficial health outcomes (16, 34, 35) and reinforcing Sncs’ role in causing disease.”
The paper relies on this without support.
Eliminating senescent cells by genetic ablation of p16Ink4a-expressing cells or by D+Q reduces hepatic steatosis.
“Elimination of Sncs by genetic ablation of p16Ink4a-expressing cells or by the senolytic drug cocktail D+Q reduces hepatic steatosis.”
The paper relies on this without support.
Many anticancer drugs and natural products have some senotherapeutic activity in vitro.
“Indeed, many anticancer drugs as well as natural products have some senotherapeutic activity in vitro.”
The paper relies on this without support.
Dasatinib has been FDA approved for clinical use since 2006.
“Dasatinib has been approved for clinical use since 2006.”
The paper relies on this without support.
Quercetin and fisetin are natural products with favorable safety profiles.
“Quercetin and fisetin are natural products with favorable safety profiles.”
The paper relies on this without support.
Rats spontaneously develop more age-related diseases common in humans, such as diabetes and sarcopenia, than mice do.
“Rats are models highly suited for studying human aging, and they spontaneously develop more age-related diseases common in humans (e.g., diabetes and sarcopenia) than mice do.”
The paper relies on this without support.
Rats are more amenable than mice to cognitive behavioral measurements, endocrine testing, physical function measurements, and cardiovascular assessments.
“Rats are more amenable than mice to cognitive behavioral measurements, endocrine (e.g., glucose tolerance) testing, physical function measurements, and cardiovascular assessments.”
The paper relies on this without support.
Genetic modification technologies in the rat now allow creation of rat models with transgenes that enable clearance of p16Ink4a-expressing cells.
“Genetic modification technologies have advanced in the rat, and it is now possible to create rat models with transgenes that enable clearance of p16Ink4a-expressing cells (e.g., an INK-ATTAC rat line).”
The paper relies on this without support.
Over one dozen FDA-approved clinical trials with D+Q, fisetin, and UBX0101 have been conducted to date.
“To date, there have been over one dozen FDA-approved clinical trials with the senolytics D+Q, fisetin, and UBX0101.”
The paper relies on this without support.
D+Q and fisetin are being tested for systemic treatment of multiple age-related conditions and diseases, including Alzheimer's disease.
“D+Q and fisetin are being tested for the systemic treatment of multiple age-related conditions and diseases, including AD.”
The paper relies on this without support.
UBX0101 is an inhibitor of the p53–MDM2 interaction and is being used locally within the joint space for osteoarthritis.
“UBX0101, an inhibitor of the p53–MDM2 interaction, is being used locally within the joint space for the treatment of osteoarthritis”
The paper relies on this without support.
Only three trials have reported results to date.
“To date, only three trials have reported results.”
The paper relies on this without support.
Aging, frailty, and multimorbidity of old age are not FDA-recognized clinical end points that warrant therapeutic intervention.
“This is because aging, frailty, and multimorbidity of old age are not FDA-recognized clinical end points that warrant therapeutic intervention.”
The paper relies on this without support.
The combination of D+Q is more effective than either agent alone.
“The combination of D+Q is more effective than either agent alone.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The number of senolytic therapies is still limited but some have been extensively used in preclinical models of disease, as exemplified by navitoclax, dual treatment with dasatinib and quercetin (D/Q), fisetin, cardiac glycosides and others 184 .”
From Hallmarks of aging: An expanding universe (2023) · cites this paper as [184]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Additionally, in mice, the removal of senescent cells either genetically or pharmacologically prevents the development of age-related adverse outcomes, underscoring the therapeutic potential of targeting these cells (Robbins et al, 2021).”
From Distinct senotypes in p16- and p21-positive cells across human and mouse aging tissues (2025) · cites this paper as Robbins et al, 2021
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, several studies have shown that elimination of senescent cells in mice either genetically or by using drugs that can kill senescent cells (senolytics) alleviates several pathologies during aging and age-related disorders2.”
From Spatial mapping of cellular senescence: emerging challenges and opportunities (2023) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Also, genetic or pharmacological elimination of senescent cells is therapeutic in many diseases modeled in mice 184”
From Hallmarks of aging: An expanding universe (2023) · cites this paper as [184]
In the citing paper
“Moreover, candidate drugs (senotherapeutics) that impact the abundance (senolytics) or behavior (senomorphics) of senescent cells have been shown to counter multiple conditions across multiple physiological systems in mouse models of aging and disease (2).”
From Exercise Counters the Age-Related Accumulation of Senescent Cells (2022) · cites this paper as [2]
In the citing paper
“As an example, senolytic therapy is clearly aimed to enhance healthspan by cells in a particular state, not all cells in an aged tissue.56”
From Asynchronous, contagious and digital aging (2021) · cites this paper as [56]
Citations
Cites
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982
The senescence-associated secretory phenotype: the dark side of tumor suppression
Coppé, J.-P., Desprez, P.-Y., Krtolica, A., & Campisi, J. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102144 · Cited by 5,206
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Epidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004 · cited 1×
“Sarcopenia is evident in up to 25% of community-dwelling individuals (46) and reflects a reduction in the cross-sectional area and the number of muscle fibers and the accumulation of fat and connective tissue.”
BackgroundClearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670
Self-citationCellular Senescence: Defining a Path Forward
Gorgoulis, V., Adams, P. D., Alimonti, A., Bennett, D. C., Bischof, O., Bishop, C., Campisi, J., Collado, M., Evangelou, K., Ferbeyre, G., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.005 · Cited by 3,225 · cited 2×
“there is not one single biomarker of Sncs (Figure 2) and that only through the simultaneous measure of multiple end points can Sncs be identified accurately (30).”
BackgroundSelf-citationNaturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876 · cited 2×
“For example, Sncs are critical during development, can suppress tumor growth, and assist with tissue repair (23, 32), but they also drive pathology, including cancer (9, 17).”
BackgroundSelf-citationGeroscience: Linking Aging to Chronic Disease
Kennedy, B. K., Berger, S. L., Brunet, A., Campisi, J., Cuervo, A. M., Epel, E. S., Franceschi, C., Lithgow, G. J., Morimoto, R. I., Pessin, J. E., et al. (2014) · Cell · doi:10.1016/j.cell.2014.10.039 · Cited by 2,764
Macrophages, inflammation, and insulin resistance
Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733 · cited 1×
“Adipose tissue becomes a major contributor to insulin resistance in old age due to changes in immune cell populations, including a shift of macrophages toward a proinflammatory phenotype and a loss of regulatory T cells, and increased release of inflammatory cytokines, including tumor necrosis factor-α (TNF-α) and ost…”
BackgroundAlzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642 · cited 1×
“8 million (with 7 million of these individuals aged 85 years or older) in 2050 (55).”
Background
Research works printed but not linked: 2
- Kirkland JL, 2007, Int. J. Obes., 31, S18
- Fuhrmann-Stroissnigg H, 2019, J. Vis. Exp., 2019, 148
Cited by
Sorted by citations
Hallmarks of aging: An expanding universe
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2023) · Cell · doi:10.1016/j.cell.2022.11.001 · Cited by 6,549
Telomere dysfunction in ageing and age-related diseases
Rossiello, F., Jurk, D., Passos, J. F., & d’Adda di Fagagna, F. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00842-x · Cited by 754
Self-citationTargeting cellular senescence with senotherapeutics: senolytics and senomorphics
Zhang, L. J., Pitcher, L. E., Prahalad, V., Niedernhofer, L. J., & Robbins, P. D. (2022) · FEBS Journal · doi:10.1111/febs.16350 · Cited by 674
Self-citationStrategies for targeting senescent cells in human disease
Gasek, N. S., Kuchel, G. A., Kirkland, J. L., & Xu, M. (2021) · Nature Aging · doi:10.1038/s43587-021-00121-8 · Cited by 501
Self-citationROS: Basic Concepts, Sources, Cellular Signaling, and its Implications in Aging Pathways
de Almeida, A. J. P. O., de Oliveira, J. C. P. L., Pontes, L. V. D. S., Júnior, J. F. D. S., Gonçalves, T. A. F., Dantas, S. H., Feitosa, M. S. D. A., Silva, A. O., & de Medeiros, I. A. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1225578 · Cited by 557
“Thereby, senescence is a promising target for treating age-related diseases and improving lifespan and healthspan [290, 291].”
Background
Metadata
- Authors
- Robbins, P. D., Jurk, D., Khosla, S., Kirkland, J. L., LeBrasseur, N. K., Miller, J. D., Passos, J. F., Pignolo, R. J., Tchkonia, T., & Niedernhofer, L. J.
- Affiliations
- University of Minnesota (US)
- Mayo Clinic (US)
- ORCID
- Venue
- Annual Review of Pharmacology and Toxicology
- Publisher
- Annual Reviews
- Published
- 2021-01-06
- Volume
- 61
- Issue
- 1
- Pages
- 779-803
- ISSN
- 0362-1642 (ISSN-L)
- 1545-4304
- PMC
- PMC7790861
- OpenAlex
- W3089880422
- Cited by
- 360
- References
- 97
- Citations by year
- 2026: 78 · 2025: 80 · 2024: 59 · 2023: 50 · 2022: 56 · 2021: 34
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Annual Review of Pharmacology and Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Noaber Foundation
- National Institutes of Health (AG062412)
- Biotechnology and Biological Sciences Research Council (BB/K017314/1)
- National Institute on Aging (P01AG043376, R56AG059676, R56AG059675, R01AG068048, R37AG013925, U19AG056278, P01AG062413, R01AG063543)
- National Cancer Institute (UG3CA268103)
- National Center for Advancing Translational Sciences (UL1 TR0002377)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Keywords
- senolytics, senescent cells, senescence-associated secretory phenotype, senotherapeutics, aging, age-related diseases, chronic inflammation, healthspan, senomorphics, drug development, clinical trials
- MeSH terms
- Aged, Aging, Pharmaceutical Preparations, Humans, Phenotype, Signal Transduction, Cellular Senescence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
